2001 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Kelsen
    Kelsen
  4. Saltz
    Saltz
  5. Norton
    Norton
  6. Bajorin
    Bajorin
  7. Kemeny
    Kemeny
  8. Scher
    Scher
  9. Ilson
    Ilson
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)
  7. Gastrointestinal Oncology Service (315)
  8. Epidemiology and Biostatistics (251)
  9. Genitourinary Oncology Service (233)
  10. Biostatistics Service (223)
  1. "antineoplastic combined chemotherapy protocols"
Formats
  1. Journal Article (1861)
  2. Conference Paper (49)
  3. Review (39)
  4. Editorial (17)
  5. Research Letter (15)
  6. Miscellaneous (8)
  7. Correspondence (6)
  8. Guidelines (5)
  9. Book Section (1)
Groups
  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)

More Groups

People
  1. Nancy Kemeny (90)
  2. Robert Motzer (88)
  3. Clifford Hudis (83)
  4. David Kelsen (83)
  5. Leonard Saltz (79)
  6. Larry Norton (77)

More People

Years
  1. 2025 (46)
  2. 2024 (133)
  3. 2023 (122)
  4. 2022 (90)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (279)
  2. Cancer (171)
  3. Clinical Cancer Research (78)
  4. Seminars in Oncology (59)
  5. Gynecologic Oncology (58)
  6. New England Journal of Medicine (58)

More Publications

Publishers
  1. American Society of Clinical Oncology (294)
  2. Elsevier Inc. (276)
  3. Wiley Blackwell (212)
  4. Springer (167)
  5. Oxford University Press (113)
  6. American Association for Cancer Research (108)

More Publishers

Results (2001)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial
    Journal Article

    Shanafelt, T. D.; Wang, X. V.; Hanson, C. A.; Paietta, E. M.; O'Brien, S.; Barrientos, J.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The ABVD’s of cooperative trials in pediatric Hodgkin lymphoma: The India experience
    Editorial

    Rodriguez-Hernandez, A.; Giulino-Roth, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Approach to resectable gastric cancer: Evolving paradigm of neoadjuvant and adjuvant treatment
    Review

    Lumish, M. A.; Ku, G. Y.
    Current Treatment Options in Oncology (2022)

    Fulltext@MSK | Save
  • Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy
    Research Letter

    Yang, J. C.; Scordo, M.; Chau, K. W.; Sauter, C. S.; Yahalom, J.
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • Phase II trial of response-based radiation therapy for patients with localized germinoma: A Children's Oncology Group study
    Journal Article

    Bartels, U.; Onar-Thomas, A.; Patel, S. K.; Shaw, D.; Fangusaro, J.; Dhall, G.; Souweidane, M.; Bhatia, A.; Embry, L.; Trask, C. L.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): A randomised, phase 3 study
    Journal Article

    Motzer, R.; Porta, C.; Alekseev, B.; Rha, S. Y.; Choueiri, T. K.; Mendez-Vidal, M. J.; Hong, S. H.; Kapoor, A.; Goh, J. C.; Eto, M.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • MATTERHORN: Phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
    Review

    Janjigian, Y. Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Marcovitz, M.; Ruscica, D.; Robbins, S. H.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma
    Journal Article

    Sihag, S.; Nussenzweig, S. C.; Walch, H. S.; Hsu, M.; Tan, K. S.; De La Torre, S.; Janjigian, Y. Y.; Maron, S. B.; Ku, G. Y.; Tang, L. H.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
    Journal Article

    Choudhury, A. D.; Higano, C. S.; de Bono, J. S.; Cook, N.; Rathkopf, D. E.; Wisinski, K. B.; Martin-Liberal, J.; Linch, M.; Heath, E. I.; Baird, R. D.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • ASO Visual Abstract: Effect of age on outcomes after neoadjuvant chemotherapy for breast cancer
    Miscellaneous

    Verdial, F. C.; Mamtani, A.; Pawloski, K. R.; Sevilimedu, V.; D'Alfonso, T. M.; Zhang, H.; Gemignani, M. L.; Barrio, A. V.; Morrow, M.; Tadros, A. B.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save